Merck, Sharp & Dohme, the American pharmaceutical giant, has agreed to pay $950 million to resolve criminal and civil claims related to the promotion of Vioxx, Justice Department officials announced Wednesday.
Under the agreement, the company will plead guilty to one count of violating the Food, Drug and Cosmetic Act as a result of introducing the painkiller into the U.S. market. Merck will pay a $321.6 million fine. It also will pay $628.36 million to resolve additional civil allegations in connection with making false statements about the drug’s cardiovascular safety and the marketing of the drug.
The federal government will receive $426.3 million and $201.9 million will be given to 43 states for Medicaid.
Merck has been under investigation for several years in connection with Vioxx, which was taken off the market in 2004. The criminal charge is related to the misbranding of Vioxx for treatment of rheumatoid arthritis before it was approved for that purpose. The civil charges are related to allegations that Merck representatives made “inaccurate, unsupported or misleading” statements about Vioxx in order to increase its sales.
“When a pharmaceutical company ignores FDA rules aimed at keeping our medicines safe and effective, that company undermines the ability of health care providers to make the best medical decisions on behalf of their patients,” said Tony West, assistant attorney general for the DOJ Civil Division. “As this plea agreement and civil settlement make clear, we will not hesitate to pursue those who skirt the proper drug approval process and make misleading statements about the safety and efficacy of their products.”
This case was handled by the Justice Department’s Civil Division and the U.S. Attorney’s Office for the District of Massachusetts. The investigation was conducted by HHS-OIG, the FBI, the Office of Criminal Investigations for the FDA, the Veterans Administration’s Office of Criminal Investigations, the Office of the Inspector General for the Office of Personnel Management, the National Association of Medicaid Fraud Control Units, and the offices of various state attorneys general.
Be aware of drugs that potentiate diabetes.
Eli Lilly Zyprexa Olanzapine issues linger.
The use of powerful antipsychotic drugs has increased in children as young as three years old. Weight gain, increases in triglyceride levels and associated risks for diabetes and cardiovascular disease. The average weight gain (adults) over the 12 week study period was the highest for Zyprexa—17 pounds. You’d be hard pressed to gain that kind of weight sport-eating your way through the holidays.One in 145 adults died in clinical trials of those taking the antipsychotic drug Zyprexa.
This was Lilly’s #1 product $5 billion per year sales,moreover Lilly also make billions more on drugs that treat diabetes.
— Daniel Haszard Zyprexa victim activist and patient.
FMI zyprexa-victims(dot)com